Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
dimetindene (dimetindene maleate)
GlaxoSmithKline Consumer Healthcare S.A.
R06AB03 օրիգինալ դեղ
dimetindene (dimetindene maleate)
1mg/ml glass bottle 20ml
drops oral (solution)
1mg/ml glass bottle 20ml
OTC
Registered
2020-11-26
1 GSK Consumer Healthcare S.A., Switzerland. CONFIDENTIAL Summary of Product Characteristics Fenistil NEW Regulatory Affairs FENISTIL 1 MG/ML ORAL DROPS Dimethindene maleate SUMMARY OF PRODUCT CHARACTERISTICS Document type: SPC Document status: Final Release date: 10 February, 2020 Number of pages: 7 Property of GSK Consumer Healthcare S.A. Confidential May not be used, divulged, published or otherwise disclosed without the consent of GSK Consumer Healthcare S.A. 2 GSK Consumer Healthcare S.A., Switzerland. CONFIDENTIAL Summary of Product Characteristics Fenistil NEW CONTENTS 1. NAME OF THE MEDICINAL PRODUCT ................................................................ 3 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ....................................... 3 3. PHARMACEUTICAL FORM .................................................................................... 3 4. CLINICAL PARTICULARS ...................................................................................... 3 4.1. Therapeutic indications .................................................................................... 3 4.2. Posology and method of administration ............................................................ 3 4.3. Contraindications............................................................................................ 3 4.4. Special warnings and special precautions for use .............................................. 3 4.5. Interactions with other medicinal products and other forms of interaction ......... 3 4.6. Pregnancy and lactation ................................................................................... 3 4.7. Effects on ability to drive and use machines...................................................... 4 4.8. Undesirable effects........................................................................................... 4 4.9. Overdose ......................................................................................................... 4 5. PHARMACOLOGICAL PROPERTIES ................................ Read the complete document